PDS Biotechnology (PDSB) Shares Down 17% Following Stock Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
PDS Biotechnology (PDSB) Announces Proposed Offering of Common Stock
June 14, 2021 4:02 PM EDTPDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune® T-cell activating technology, today announced that it has commenced an underwritten public offering of shares of its common stock.... More
